-- Mary Elizabeth Dallas
TUESDAY, Aug. 27 (HealthDay News) -- Testing for certain
proteins in spinal fluid may help doctors diagnose Parkinson's
disease earlier and determine how fast the movement disorder is
likely to advance, according to new research.
The team from the Perelman School of Medicine at the University
of Pennsylvania said their discovery of these protein "biomarkers"
might also aid in the development of new Parkinson's
"Biomarkers for Parkinson's disease such as these could help us diagnose patients earlier," study senior author Leslie Shaw, a professor of pathology and laboratory medicine at Penn Medicine, said in a university news release.
Shaw and Dr. John Trojanowski are co-leaders in the bioanalytics
core for the Parkinson's Progression Markers Initiative (PPMI), an
international study sponsored by The Michael J. Fox Foundation for
Parkinson's. They led a team that collected spinal fluid from 102
people. Of these, 63 had early, untreated Parkinson's disease and
39 did not have the disorder (the "control" group).
The investigators examined the levels of five specific
substances in the spinal fluid, including amyloid beta, total tau,
phosphorylated tau, alpha synuclein and the ratio of total tau to
The findings revealed that, compared with the healthy control
group, people with early stage Parkinson's had lower levels of
amyloid beta, tau and alpha synuclein in their spinal fluid.
In addition, patients with lower levels of tau and alpha
synuclein had more problems with movement, the study authors noted
in the report published Aug. 26 in
The researchers found that patients with early stage Parkinson's
and low levels of amyloid beta and tau were more likely to
experience falls, freezing and trouble walking. Previous research
has shown that this type of motor dysfunction in Parkinson's is
associated with more functional disability and a faster decline in
"We are hoping to identify subgroups of Parkinson's patients whose disease is likely to progress at a different rate, as early as possible," noted Trojanowski, who is also director of the Penn Udall Center for Parkinson's Research. "Early prediction is critical, for both motor and dementia symptoms," he said in the news release.
PPMI trial site study leader and professor of neurology, Dr.
Matthew Stern, added in the news release that "in addition to
biomarker tests, validating risk factors could enable earlier
detection of the disease and open new avenues in the quest for
therapies that could slow or stop disease progression." Stern is
also director of Penn's Parkinson's Disease and Movement Disorders
The study authors pointed out that more research is needed to
evaluate and confirm the spinal fluid testing procedure.
The U.S. National Institute of Neurological Disorders and Stroke
provides more information on
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.